



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#13
9/15/00
HR

Applicant: Walter H. Gunzburg, Robert M. Saller and Brian Salmons
Application No.: 09/035,596 Group Art Unit: 1633
Filed: March 5, 1998 Examiner: S. Chen

Title: The Use of the WAP or MMTV Regulatory Sequences For Targeted Expression of Linked Heterologous Genes in Human Mammary Cells, Including Human Mammary Carcinoma Cells



CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231	
on	8-31-00
Date	Signature
Sandra J. Jassal	
Typed or printed name of person signing certificate	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)
- ☐ under 37 CFR 1.97(b), or
(Within three months of filing national application; or date of entry of the national stage in international application; or before mailing date of first office action on the merits or before the first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. 1.114; whichever occurs last)
- ☒ under 37 CFR 1.97(c) together with either:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, or
- ☒ a \$240.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, and
- ☐ a Petition under 37 CFR 1.97(d)(2), and
- ☐ a \$130.00 petition fee set forth in 37 CFR 1.17(i).
(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)
- ☐ Applicant requests that the attached IDS and cited reference(s) [] be placed in the application filewrapper.
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Enclosed herewith is form PTO-1449:

- ☐ Copies of the cited references are enclosed.
- ☒ Copies of cited references (AQ, AL2-AP2 and AY) are enclosed except those entered in prior application, U.S. Serial No. [], and references that are not required to be submitted under 37 CFR 1.98.
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- ☒ Co-pending patent applications:

Exam-
iner's
Initial

- U.S. Patent Application Serial No.: 08/808,827, filed February 28, 1997, entitled "Non Self-Inactivating, Expression Targeted Retroviral Vectors," by Gunzburg et al.;
Attorney's Docket No.: 2316.1001-000 (formerly GSF97-01A).
- U.S. Patent Application Serial No.: 08/925,214, filed September 8, 1997, entitled "Novel Recombinant DNA Vectors For Gene Therapy," by Gunzburg et al.;
Attorney's Docket No.: 2316.1002-000 (formerly GSF97-02A)1.
- U.S. Patent Application Serial No.: 08/999,690, filed September 8, 1997, entitled "Vectors Carrying Therapeutic Genes Encoding Antimicrobial Peptides" by Gunzburg et al.;
Attorney's Docket No.: 2316.1003-000 (formerly GSF97-03A).
- U.S. Patent Application Serial No.: 08/996,460, filed December 23, 1997, entitled "Encapsulated Cells Producing Viral Particles" by Saller et al.;
Attorney's Docket No.: 2316.1005-000 (formerly GSF97-05A).
- U.S. Patent Application Serial No.: 09/058,546, filed April 10, 1998, entitled "Retroviral Vectors Carrying Senescent Cell Derived Inhibitors 1 (SDI-1) or Antisense SDI-1 Nucleotide Sequences" by Gunzburg et al.;
Attorney's Docket No.: 2316.1008-000 (formerly GSF98-02A).
- U.S. Patent Application Serial No.: 09/160,067, filed September 24, 1998, entitled "Encapsulated Cells Producing Cytochrome P450," by Gunzburg et al.;
Attorney's Docket No.: 2316.1010-000 (formerly GSF98-04A)
- U.S. Patent Application Serial No.: 09/442,979, filed November 18, 1999, entitled "Encapsulated Cells Producing Cytochrome P450," by Gunzburg et al.;
Attorney's Docket No.: 2316.1010-001.

Examiner

Date

The Examiner is requested to return a copy of the above list of co-pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.


Method of payment:

- [X] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.
A copy of this Statement is enclosed.
- [] Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- [] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By



Anne J. Collins

Registration No.: 40,564

Telephone: (781) 861-6240

Facsimile: (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated: August 31, 2000